Optiscan Imaging establishes US commercial operation in Minnesota

Latest News

Australian company Optiscan Imaging (ASX:OIL) has announced the establishment of a new commercial operation in the US.

Optiscan is focused on developing, manufacturing, and commercialising confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications.

The US operation has been established as a standalone legal entity, along with new business premises, regional leadership, and operational, constitutional, and taxation obligations.

The US office will be based in Minnesota within a medical innovation precinct.

Optiscan CEO and managing director Dr Camile Farah said, “The decision to establish a US commercial operation in Minnesota follows a period of considered review and analysis of various business models, commercial structures, and healthcare ecosystems.

"The pursuit of a direct market model reflects our future growth aspirations, which includes development of new devices for large addressable markets, and the anticipated adoption of our unique slide-free, biopsy-free technology.

"Our partnership with, and membership of, the Medical Alley and new commercial hub in Minnesota, puts Optiscan at the epicentre of health innovation and care, aligning well with our objective of establishing a new standard of digital pathology and precision surgery across the North American region.”

Medical Alley vice president of innovation, Frank Jaskulke, added, “We are delighted to be partnering with Optiscan and helping them establish a scalable US operation. Their technology is both unique and ground-breaking, with the potential to make an enormous difference to healthcare professionals and patient outcomes.

"We look forward to seeing Optiscan’s contribution within the MedTech innovation epicentre of Minnesota, their development across the United States, and benefit to clinical and patient outcomes with their technology, which will be significant.”